The Next Step for Hemispherx's Ampligen

Another week has passed and still no word from Hemispherx Biopharma(HEB Quote) on the approval of its chronic fatigue syndrome drug Ampligen.

Here's a prediction, more of a hunch, based on recent events: Hemispherx will soon announce that because of the current flu pandemic, the company has decided to withdraw its Ampligen application from the U.S. Food and Drug Administration. Instead, the company will focus all its resources on working with its "international partners" to develop Ampligen as an adjuvant flu vaccine booster.

Why would Hemispherx take this action? Because the company suspects that the FDA isn't going to approve Ampligen for chronic fatigue syndrome any time soon and certainly not before the company runs another lengthy and expensive clinical trial. The first study was a mess, as I've reported. ...